Information  X 
Enter a valid email address

PuriCore Plc (RLM)

  Print      Mail a friend       Annual reports

Thursday 13 February, 2014

PuriCore Plc

Middle East Wound Care Marketing Agreement

RNS Number : 9551Z
PuriCore Plc
13 February 2014
 



13 February 2014

 

PuriCore Signs Middle East Wound Care Marketing Agreement

 

PuriCore plc (LSE: PURI), a global company focused on safe and effective protection against the spread of infectious pathogens, today announces that the Company has signed a marketing and distribution agreement with Ueno Corporation for Vashe® Wound Therapy in select Middle East and North African counties. Ueno is a trading company headquartered in Japan with well-established health care product distribution, including multiple complementary wound care and diabetic foot products, in 15 Middle Eastern and North African (MENA) countries including Saudi Arabia, Egypt, Jordan, Kuwait, and the UAE.

 

 

Michael Ashton, Executive Chairman of PuriCore, said:

"Leading hospitals, wound care centres, and home healthcare providers use Vashe Wound Therapy as a safe and effective treatment for chronic and acute wounds, including diabetic ulcers and burns. Ueno offers long-standing market presence in the MENA region and we are delighted to have such a strong marketing partner.  Promising international marketing agreements, such as this one, offer significant opportunity for long-term growth for our Wound Care product line in new geographies."

 

According to Global Industry Analysts, the global wound care market is expected to reach $22.8 billion by 2017 resulting from ageing populations and an increase in people affected by diabetes, obesity, and hospital-acquired infections.

 

About Vashe Wound Therapy

Vashe Wound Therapy is a safe and effective non-antibiotic alternative wound treatment for acute and chronic wounds that is demonstrated to be extremely gentle and hypoallergenic. Vashe has been rigorously safety tested and is non-cytotoxic, non-irritating, non-sensitizing, and has no oral toxicity or clinical contraindications for use. Vashe Wound Therapy is intended for use in cleansing, irrigating, moistening, and debriding acute and chronic dermal lesions, such as Stage I-IV pressure ulcers, stasis ulcers, diabetic ulcers, post-surgical wounds, first- and second-degree burns, abrasions, and minor irritations of the skin. Vashe Wound Therapy is available by prescription only.

 

Enquiries:

UK

US

FTI Consulting

Sage Strategic Marketing

Simon Conway/Mo Noonan

Jennifer Guinan

Victoria Foster Mitchell

+1 610.410.8111

+44 (0) 20 7831 3113

[email protected]

 

About PuriCore

 

PuriCore plc (LSE: PURI) is a global company focused on safe and effective protection against the spread of infectious pathogens without causing harm to human or animal health or to the environment. PuriCore's antimicrobial technology and complementary products are used in well-established core businesses and emerging sectors of two broad markets: Health Sciences and Food & Agriculture. In the Health Sciences market, PuriCore is the leading full provider of all products and services required for a safe, efficient, and compliant endoscope decontamination to protect patients and staff in UK hospitals. PuriCore's breakthrough wound care technology is used to treat chronic and acute wounds including diabetic ulcers and burns in humans, for atopic dermatitis as private-labelled dermatologic treatments for humans, and to manage wounds in all species of companion and farm animals in the animal health segment. In the Food & Agriculture market, PuriCore's portfolio is used by three of the top-five US supermarket retailers to provide savings in labour costs and improvements in inventory loss and to address cross contamination of pathogens on fresh produce and floral products. In addition, the Company is progressing its research and development programmes on the use of its technology as an agricultural fungicide. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK. To receive additional information on PuriCore, visit www.puricore.com.

 

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions.  Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRLLFETFDIFLIS

a d v e r t i s e m e n t